U.S. stock night trading opens with fluctuations: System1 rises 7.69% in night trading; SurgePays rises 7.30% in night trading

U.S. Stock Night Market Opening Movements System1, up 7.69% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. SurgePays, up 7.30% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Top Gainers in the U.S. Night Market Intellia Therapeutics, up 27.81% in the night market. Based on recent key news: On April 25, Intellia announced it would release the topline results of its global Phase 3 HAELO trial on April 27. This trial involves lonvoguran ziclumeran for the treatment of hereditary angioedema. This news is seen as a potential milestone for its platform's clinical validation, driving the stock price up. On April 24, Intellia's stock price fell 14.11% in regular trading but rose 19.27% in after-hours trading. This volatility reflects market expectations for the upcoming clinical data release. On April 25, Intellia partnered with strategic collaborators to expand the impact of its genome editing methods. Although analysts rated Intellia as hold, market attention to its technological potential has increased. The gene editing industry is gaining attention, leading to heightened market volatility. Organon, up 18.12% in the night market. Based on recent key news: On April 26, Sun Pharmaceutical announced a cash acquisition of Organon, with a transaction valuation of approximately $11.75 billion. This news drove Organon's stock price up. Source: Reuters On April 25, Sun Pharmaceutical had previously submitted multiple offers to acquire Organon, with the latest bid at $13 billion, setting a record for the company's largest acquisition. This news sparked market interest in Organon, significantly boosting its stock price. Source: Zhitong Finance On April 27, Sun Pharmaceutical and Organon reached a final agreement to acquire all outstanding shares of Organon at a price of $14 per share. This transaction was approved by both boards, further driving the stock price up. Source: Reuters The pharmaceutical industry consolidation is accelerating, with attention to market volatility risks. Oncolytics Biotech, up 15.53% in the night market. Based on recent key news: On April 24, Oncotelic Therapeutics Inc. released an important announcement that boosted Oncolytics Biotech's stock price. The announcement involved the company's latest research progress in cancer treatment, enhancing market confidence in its future growth potential, resulting in a 15.53% stock price increase. Source: GlobeNewswire Recently, the biotechnology industry has performed strongly overall, with increased investor interest in innovative drugs driving up the stock prices of related companies. There has been a noticeable inflow of funds into the industry, further supporting the rise in Oncolytics Biotech's stock price. The U.S. stock market is generally performing well, with optimistic investor sentiment driving a widespread increase in the biotechnology sector. Positive macroeconomic data has enhanced market confidence, indirectly promoting the rise in Oncolytics Biotech's stock price. The biotechnology industry has shown strong performance recently, with significant capital inflows